CHICAGO — A Fas inhibitor showed strong efficacy signals and demonstrated neuroprotection in patients with more than 8 days of macula-off rhegmatogenous retinal detachment, according to a study ...

The procedure your doctor uses depends on how severe the detachment is and other factors. Complications of Myopic Macular Degeneration Having high myopia also puts you at risk for retinal tears or ...

OCT and Posterior Uveitis . Patients with posterior uveitis can develop complications including macular edema, epiretinal membrane, vasculitis, retinal artery or vein occlusions, retinal necrosis ...

Rhegmatogenous: This is linked to retinal tears and is the most common type of retinal detachment. Such tears can be caused by aging, being nearsighted, having an injury, or having had eye surgery.

Without treatment, however, the whole retina can peel off, and a person risks losing the vision from that eye. ... In retinal detachment, the macula may or may not become detached.

Finally, it peels off the macula and this leads to posterior vitreous detachment. ... Operculated tears are produced by traction and progress to retinal detachment in up to 20% of cases.

The retina is the tissue inside the back of the eye that changes what you see into electrical signals that travel to the brain. When the retina splits, tiny lumps called cysts form between the layers.

Fas Inhibition with ONL1204 for Macula-off Rhegmatogenous Retinal Detachment (RRD): Study Population Data on a Phase 2, Multicenter, Randomized, Sham-controlled, Single-Masked, Clinical Trial .

The company’s later-stage clinical development program for ONL1204 currently includes a Phase 2 study in the U.S. for the treatment of macular-off retinal detachment, a condition for which the ...

ANN ARBOR, Mich., April 12, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with ...

ANN ARBOR, Mich., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal ...